Eintrag weiter verarbeiten
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Blood, 126, 2015, 13, S. 1551-1554 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Deininger, Michael Radich, Jerald Burn, Timothy C. Huber, Reid Paranagama, Dilan Verstovsek, Srdan Deininger, Michael Radich, Jerald Burn, Timothy C. Huber, Reid Paranagama, Dilan Verstovsek, Srdan |
|---|---|
| author |
Deininger, Michael Radich, Jerald Burn, Timothy C. Huber, Reid Paranagama, Dilan Verstovsek, Srdan |
| spellingShingle |
Deininger, Michael Radich, Jerald Burn, Timothy C. Huber, Reid Paranagama, Dilan Verstovsek, Srdan Blood The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis Cell Biology Hematology Immunology Biochemistry |
| author_sort |
deininger, michael |
| spelling |
Deininger, Michael Radich, Jerald Burn, Timothy C. Huber, Reid Paranagama, Dilan Verstovsek, Srdan 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2015-03-635235 <jats:title>Key Points</jats:title> <jats:p>The JAK2p.V617F mutation leads to constitutive activation of JAK2 and contributes to dysregulated JAK signaling in myelofibrosis. Long-term ruxolitinib treatment decreased JAK2p.V617F allele burden, with some patients achieving complete or partial molecular remissions.</jats:p> The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis Blood |
| doi_str_mv |
10.1182/blood-2015-03-635235 |
| facet_avail |
Online Free |
| finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE1LTAzLTYzNTIzNQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE1LTAzLTYzNTIzNQ |
| institution |
DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 |
| imprint |
American Society of Hematology, 2015 |
| imprint_str_mv |
American Society of Hematology, 2015 |
| issn |
0006-4971 1528-0020 |
| issn_str_mv |
0006-4971 1528-0020 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
deininger2015theeffectoflongtermruxolitinibtreatmentonjak2pv617falleleburdeninpatientswithmyelofibrosis |
| publishDateSort |
2015 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood |
| source_id |
49 |
| title |
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_unstemmed |
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_full |
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_fullStr |
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_full_unstemmed |
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_short |
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_sort |
the effect of long-term ruxolitinib treatment on jak2p.v617f allele burden in patients with myelofibrosis |
| topic |
Cell Biology Hematology Immunology Biochemistry |
| url |
http://dx.doi.org/10.1182/blood-2015-03-635235 |
| publishDate |
2015 |
| physical |
1551-1554 |
| description |
<jats:title>Key Points</jats:title>
<jats:p>The JAK2p.V617F mutation leads to constitutive activation of JAK2 and contributes to dysregulated JAK signaling in myelofibrosis. Long-term ruxolitinib treatment decreased JAK2p.V617F allele burden, with some patients achieving complete or partial molecular remissions.</jats:p> |
| container_issue |
13 |
| container_start_page |
1551 |
| container_title |
Blood |
| container_volume |
126 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347153535860742 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:50:46.383Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+effect+of+long-term+ruxolitinib+treatment+on+JAK2p.V617F+allele+burden+in+patients+with+myelofibrosis&rft.date=2015-09-24&genre=article&issn=1528-0020&volume=126&issue=13&spage=1551&epage=1554&pages=1551-1554&jtitle=Blood&atitle=The+effect+of+long-term+ruxolitinib+treatment+on+JAK2p.V617F+allele+burden+in+patients+with+myelofibrosis&aulast=Verstovsek&aufirst=Srdan&rft_id=info%3Adoi%2F10.1182%2Fblood-2015-03-635235&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347153535860742 |
| author | Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan |
| author_facet | Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan, Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan |
| author_sort | deininger, michael |
| container_issue | 13 |
| container_start_page | 1551 |
| container_title | Blood |
| container_volume | 126 |
| description | <jats:title>Key Points</jats:title> <jats:p>The JAK2p.V617F mutation leads to constitutive activation of JAK2 and contributes to dysregulated JAK signaling in myelofibrosis. Long-term ruxolitinib treatment decreased JAK2p.V617F allele burden, with some patients achieving complete or partial molecular remissions.</jats:p> |
| doi_str_mv | 10.1182/blood-2015-03-635235 |
| facet_avail | Online, Free |
| finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC0yMDE1LTAzLTYzNTIzNQ |
| imprint | American Society of Hematology, 2015 |
| imprint_str_mv | American Society of Hematology, 2015 |
| institution | DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1 |
| issn | 0006-4971, 1528-0020 |
| issn_str_mv | 0006-4971, 1528-0020 |
| language | English |
| last_indexed | 2024-03-01T17:50:46.383Z |
| match_str | deininger2015theeffectoflongtermruxolitinibtreatmentonjak2pv617falleleburdeninpatientswithmyelofibrosis |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 1551-1554 |
| publishDate | 2015 |
| publishDateSort | 2015 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood |
| source_id | 49 |
| spelling | Deininger, Michael Radich, Jerald Burn, Timothy C. Huber, Reid Paranagama, Dilan Verstovsek, Srdan 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood-2015-03-635235 <jats:title>Key Points</jats:title> <jats:p>The JAK2p.V617F mutation leads to constitutive activation of JAK2 and contributes to dysregulated JAK signaling in myelofibrosis. Long-term ruxolitinib treatment decreased JAK2p.V617F allele burden, with some patients achieving complete or partial molecular remissions.</jats:p> The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis Blood |
| spellingShingle | Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan, Blood, The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis, Cell Biology, Hematology, Immunology, Biochemistry |
| title | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_full | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_fullStr | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_full_unstemmed | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_short | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| title_sort | the effect of long-term ruxolitinib treatment on jak2p.v617f allele burden in patients with myelofibrosis |
| title_unstemmed | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis |
| topic | Cell Biology, Hematology, Immunology, Biochemistry |
| url | http://dx.doi.org/10.1182/blood-2015-03-635235 |